| |
Company
[ News ] [ Our People ] [ Our Partners ]
Our People
[ Management Team ] [ Scientific Advisors ] [ Board of Directors ]
Board of Directors
Erich
Mohr, Ph.D., R.Psych.
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.
Erich Mohr, Ph.D., R.Psych, is the Chairman and CEO of MedGenesis
Therapeutix Inc. which he founded in 2005. Dr. Mohr, a Professor of
Medicine and Psychology at the University of Ottawa until 1997 has over
20 years of experience in experimental therapeutics of CNS disorders. He
is credited with over 150 publications, books, book chapters and
abstracts and has edited the Handbook of Clinical Trials: The
neurobehavioral approach. Dr. Mohr has chaired and/or served on several
regulatory advisory panels for the approval of new products for the
treatment of neurodegenerative disease and is the former Chairman and
Chief Executive Officer of CroMedica Global Inc. (merged with PRA
International in 2002) and the co-founder of several biotechnology
companies. His most recent position was with PRA International, where he
served as Chief Scientific Officer. PRA is one of the top 5 contract
research organizations in the world and is listed on NASDAQ. Over the
course of his career, Dr. Mohr has overseen and/or participated in
dozens of clinical development programs resulting in a number of
approved drugs.
Patrick
(Pat) K. Donnelly
Former President & CEO, PRA International
Mr. Donnelly is the former President & CEO, and Board Member of PRA
International (NASDAQ: PRAI). Having joined the company in 1994, he was
instrumental in directing PRA's dramatic growth from a small regional
contract research organization to one of the top global players in the
industry with over $335 million in revenue. During his tenure as Chief
Financial Officer and Chief Operating Officer, then as President, and in
2002 as CEO, he executed and integrated thirteen strategic international
acquisitions as well as lead the company through its IPO in 2004, and
subsequent successful secondary offering in 2005 both raising over $275
million and stock appreciation of 50% since the IPO. In 2006, PRA
International was named to Forbes' Top 200 Best Small Companies and in
2005 it was ranked 55th in BusinessWeek's Top 100 Growth Companies.
Prior to his tenure at PRA, he was President of Virginia Capital, L.P.
and Vedcorp, LLC, two affiliated venture capital firms. He also spent
eight years with BancBoston Capital. Mr. Donnelly graduated from The
Pennsylvania State University with a MBA in 1984 and a BS from the
University of Missouri in 1980.
Ann C. Kessler
Former Director, International Project Management, Hoffmann - La Roche
Dr. Ann C. Kessler has 27 years of full-time pharmaceutical industry
experience in the United States and Europe with Hoffmann - La Roche,
where she served as Director of International Project Management and was
responsible for global project development decisions. She also held
previous positions as Director of the Division of Exploratory Research,
the Departments of Pharmacology and Chemotherapy and the Department of
Biochemical Nutrition. Her managerial responsibilities in Research and
Development concerned the discovery and development of novel drugs for
global registration and launch in a number of therapeutic areas,
including nervous system disorders. She has authored over 150
publications, books, book chapters and abstracts dealing with obesity,
lipid metabolism and appetite regulation. She holds 16 patents
concerning pharmacological approaches to diseases.
Armin M. Kessler
Former Chief Operating Officer, Hoffman-La Roche
Dr. Armin Kessler has over 35 years experience in the global
pharmaceutical industry. His last appointment prior to retirement was
Chief Operating Officer of Hoffmann-La Roche in Basel, Switzerland.
Earlier key positions included Director of Pharmaceutical Marketing
Worldwide for Sandoz, and President of Sandoz KK in Japan. In addition
he served as President of the European Federation of Pharmaceutical
Industry Associations. Armin Kessler has a B Sc. in Physics and
Chemistry from the University of Pretoria, a B. Sc. in Chemical
Engineering from the University of Cape Town, an Juris Doctorate from
Seton Hall University and an honorary doctorate in Business
Administration from the University of Pretoria. He is a registered
Patent Attorney at the USA Patent Office.
Hector MacKay-Dunn
Senior Partner, Farris, Vaughan, Wills & Murphy LLP
Hector is a Senior Partner at Farris, Vaughan, Wills & Murphy LLP which is among Canada’s leading law firms, where Mr. MacKay-Dunn advises private and public high growth companies in a
broad range of industries on domestic and cross-border private and public securities offerings, mergers and acquisitions, tender offers, and international partnering transactions. Mr.
MacKay-Dunn is recognized by Lexpert, the most respected legal publication in Canada, as among the Top 100 Canada/US Cross-Border Corporate Lawyers in Canada and among Canada’s leading lawyers
in mergers and acquisitions, technology, and biotechnology. Hector holds the highest (“AV” Pre-eminent) legal ability rating from Martindale-Hubbell, an authoritative and global source for
identifying leading lawyers and law firms and the Best Lawyers in Canada ranks him as a national leader in Technology and Biotechnology. Hector was appointed Queen’s Counsel in 2003. Hector is
the immediate past Chair of the British Columbia Innovation Council, the Province’s lead agency with the mandate to advance ideas into investment-ready companies in the areas of science and
technology , a director of British Columbia Leading Edge Endowment Fund, British Columbia’s $56 million program to attract top researchers to B.C.’s universities and LifeSciences BC and a
former director of Genome British Columbia.
Colin Mallet
Former President and Chief Executive Officer
Sandoz Canada (now Novartis, Canada)
Colin Mallet is a professional director with extensive commercial
experience in the pharmaceutical/biotech industry. He has held senior
executive positions in the pharmaceutical industry in UK, Switzerland,
Sweden, S.E. Asia and Canada. He was President and CEO of Sandoz Canada
Inc. (now Novartis) for 7 years and is a past Chair of the Canadian
Association of Research-based Pharmaceutical companies. He has been a
director of more than a dozen Biotech/Pharma companies at various stages
of development. He currently serves on the boards of 3 public Biotech
companies and is Chair of the Corporate Governance committees for each
of these companies. He holds a B.A.(Econ.) from Cambridge and is a
graduate of both the Harvard Advanced Management Program and the
Canadian ICD Corporate Governance College.
Ken Newport
Former President, CroMedica Global Inc.
Ken Newport is an entrepreneur and life sciences business executive.
As a graduate from the University of Waterloo and a Chartered
Accountant, Mr. Newport had early success in the financial services
industry and served as a partner in a Chartered Accounting firm. His
focus changed to life sciences in the mid nineties with the formation of
CroMedica Global Inc., a contract research organization. As co-founder
and President he witnessed CroMedica's growth to 600 employees within
six years. By the time that CroMedica merged with PRA International Inc.
in 2002 CroMedica had annual revenues of over $40 million with 13
offices in 9 countries. The combined company became one of the 5 largest
contract research organizations in the world with 2,600 employees. Mr.
Newport served as a Senior Vice President and Executive Committee member
for the last three years until his recent retirement. Mr. Newport was
also a founding member of Global Biomedical Capital Corporation, Zelos
Therapeutics Inc., Prime Trials Inc. and other life science
organizations. He currently serves as the Chairman of the Ottawa Life
Sciences Council.
Page last updated:
29 June 2010
|
|